In this study, we have examined the interaction of hyaluronan (HA)-CD44 with IQGAP1 (one of the binding partners for the Rho GTPase Cdc42) in SK-OV-3.ipl human ovarian tumor cells. Immunological and biochemical analyses indicated that IQGAP1 (molecular mass of ϳ190 kDa) is expressed in SK-OV-3.ipl cells and that IQGAP1 interacts directly with Cdc42 in a GTPdependent manner. Both IQGAP1 and Cdc42 were physically linked to CD44 in SK-OV-3.ipl cells following HA stimulation. Furthermore, the HA-CD44-induced Cdc42-IQGAP1 complex regulated cytoskeletal function via a close association with F-actin that led to ovarian tumor cell migration. In addition, the binding of HA to CD44 promoted the association of ERK2 with the IQGAP1 molecule, which stimulated both ERK2 phosphorylation and kinase activity. The activated ERK2 then increased the phosphorylation of both Elk-1 and estrogen receptor-␣ (ER␣), resulting in Elk-1-and estrogen-responsive element-mediated transcriptional up-regulation. Down-regulation of IQ-GAP1 (by treating cells with IQGAP1-specific small interfering RNAs) not only blocked IQGAP1 association with CD44, Cdc42, F-actin, and ERK2 but also abrogated HA-CD44-induced cytoskeletal function, ERK2 signaling (e.g. ERK2 phosphorylation/activity, ERK2-mediated Elk-1/ER␣ phosphorylation, and Elk-1/ ER␣-specific transcriptional activation), and tumor cell migration. Taken together, these findings indicate that HA-CD44 interaction with IQGAP1 serves as a signal integrator by modulating Cdc42 cytoskeletal function, mediating Elk-1-specific transcriptional activation, and coordinating "cross-talk" between a membrane receptor (CD44) and a nuclear hormone receptor (ER␣) signaling pathway during ovarian cancer progression.
Ovarian cancer cells are characterized by their ability to freely invade the peritoneal cavity, which is consistent with the well known aggressiveness and high morbidity rate of ovarian tumors (1) (2) (3) . A number of studies have aimed at identifying specific molecule(s) expressed in ovarian carcinomas that correlate with tumor cell invasive behaviors. Among such candidate molecules is CD44 (a major hyaluronan (HA) 1 receptor) (4) , which belongs to a family of multifunctional transmembrane glycoproteins expressed in ovarian tumor cells and carcinoma tissues (5) (6) (7) (8) (9) . CD44 has been found to interact with HA at the N terminus of its extracellular domain (10 -12) . Ovarian cancer cells express CD44 isoforms that cause very strong cell adhesion to HA-enriched peritoneal mesothelium (8, 9, 13, 14) . A significant reduction in tumor implants has been found to occur in nude mice 5 weeks after intraperitoneal injection of ovarian cancer cells incubated with anti-CD44 antibody compared with injected cells pretreated with antibodies against other cell-surface proteins (8, 9) . These findings suggest that CD44 interaction with HA may be one of the important requirements for the peritoneal spread of ovarian cancer. However, the cellular and molecular mechanisms controlling the ability of CD44-positive ovarian tumor cells to undergo cancer progression at HA-enriched extracellular matrix within the peritoneal cavity remain poorly understood.
The binding of HA to CD44 isoforms triggers direct "crosstalk" between two different tyrosine kinase (e.g. p185
HER2 tyrosine kinase (5) and c-Src kinase (6))-linked signaling pathways (cell growth versus cell migration, respectively) in ovarian tumor cells. Recent studies have shown that HA-CD44 interaction in caveolin/cholesterol-enriched lipid raft microdomains plays an important role in promoting membrane-cytoskeleton association and stimulating several intracellular signaling pathways (e.g. Ca 2ϩ mobilization, cellular pH changes, Rho signaling, phosphatidylinositol 3-kinase/Akt activation), leading to the onset of cytoskeletal function and ovarian tumor cell-specific behaviors (e.g. cell survival, growth, migration, and invasion) (15) (16) (17) . These findings clearly demonstrate that CD44 plays a pivotal role in activating oncogenic signaling, leading to ovarian tumor cell function.
Members of the Rho subclass of the Ras superfamily (small molecular mass GTPases, e.g. RhoA, Rac1, and Cdc42) are known to be associated with changes in the membrane-linked cytoskeleton (18) . For example, activation of RhoA, Rac1, and Cdc42 has been found to produce specific structural changes in the plasma membrane-cytoskeleton associated with membrane ruffling, lamellipodia, filopodia, and stress fiber formation (18) .
The rationale for our present focus on Rho GTPase-related signaling is based on previous reports suggesting that CD44-associated cytoskeletal proteins (e.g. ankyrin and ERM) and certain tumor cell-specific phenotypes are dependent on Rho GTPase activation (19 -21) . Furthermore, overexpression of Rho GTPases in human tumors often correlates with a poor cancer prognosis (22, 23) . Consequently, coordinated Rho GTPase signaling is considered to be a possible mechanism underlying cell growth and migration, both of which are obvious prerequisites for metastasis (24, 25) .
In the search for additional cellular targets of HA-CD44-activated Rho GTPases that correlate with metastatic behavior in ovarian tumor cells, a molecule identified as IQGAP1 (a 190-kDa protein, one of the downstream effectors of Cdc42) has been detected (26, 27) . IQGAP1 inhibits the intrinsic GTPase activity of Cdc42, thereby significantly increasing the cellular levels of active Cdc42 (28 -32) . This molecule contains numerous functional domains and motifs found in many signal transduction proteins and oncoproteins. These structural domains include four putative calmodulin-binding (IQ) motifs, a calponin homology domain, a polyproline-binding (WW) domain, and a Ras GTPase-activating protein-related domain (26, 27) . Some of these motifs are involved in IQGAP1 interaction with specific proteins, such as Cdc42 (28 -34) , Rac (33, 34) , actin (30, 35, 36) , calmodulin (29, 30) , ERK2 (37) , E-cadherin (38) , and ␤-catenin (39) . The establishment of physical linkage between IQGAP1 and its binding partners has been shown to generate several important biological activities. For example, Cdc42-IQGAP1 binding mediates oncogenic signaling events that result in the activation of the actin cytoskeleton (28 -36) and tumor cell migration/ invasion (40) . IQGAP1 binding to ␤-catenin promotes both the rearrangement of the cadherin cell adhesion complex (41, 42) and transcriptional activation (39) . Moreover, IQGAP1-ERK2 association modulates the Ras/MAPK pathways (in particular, ERK signaling) (37) . These findings suggest that IQGAP1 not only serves as a scaffolding protein (mediating multiprotein complex assembly), but also directly participates in cytoskeleton activation and signaling coordination.
ERKs, members of the MAPK family, are known to be activated by receptor tyrosine kinases, cytokine receptors, and G-protein-coupled receptors (43, 44) . In particular, ERK phosphorylation of certain target proteins is directly involved in transcriptional activation by coordinating extracellular cues and intracellular signals (43, 44) . For example, during epidermal growth factor (EGF) stimulation or integrin signaling, ERK activation is coupled with the phosphorylation of specific target molecules, including transcription factors (e.g. the ternary complex factor Elk-1) (45, 46) and the nuclear hormone receptor (e.g. estrogen receptor) (47, 48) , resulting in cyclin D 1 expression and cell cycle progression (45) (46) (47) (48) (49) . Furthermore, growth factors have been found to activate ERK and to augment estradiol-mediated activation of nuclear hormone receptors/estrogen receptors during malignant transformation (47) (48) (49) . Previous studies indicate that HA interaction with the hyaluronan receptor RHAMM regulates ERK activity (50) . Most importantly, HA-activated ERK signaling participates in the up-regulation of certain transcription factors (e.g. NF-B and AP-1) (50, 51) and cell growth and cell migration (50) . Although ERK activation is closely associated with HA and RHAMM signaling, the regulatory mechanisms that modulate ERK-mediated transcriptional activation and cellular functions in HA-CD44-stimulated ovarian cancer progression are not well understood.
In this study, we have described a new HA-CD44-mediated oncogenic mechanism occurring in ovarian tumor cells. Specifically, we have focused on CD44 interactions with IQGAP1 during HA signaling in SK-OV-3.ipl ovarian tumor cells. Our results indicate that HA-CD44-stimulated IQGAP1 binds to both Cdc42 and ERK (in particular, ERK2). These interactions enhance F-actin binding and promote ERK activation, leading to the phosphorylation of Elk-1 and estrogen receptor (ER)-␣, Elk-1-specific transcriptional up-regulation, and estrogen-responsive element (ERE) reporter gene activation, as well as ovarian tumor cell migration. Down-regulation of IQGAP1 (by treating cells with IQGAP1-specific small interfering RNAs (siRNAs)) effectively blocks HA-CD44-stimulated cytoskeletal function, ERK signaling, and ovarian tumor cell behaviors. These findings suggest that HA-CD44-activated IQGAP1 plays an essential role in regulating Cdc42-cytoskeleton interaction and in modulating ERK activity required for Elk-1 and nuclear hormone receptor (ER␣) transcriptional up-regulation and ovarian cancer progression.
MATERIALS AND METHODS
Cell Culture-The SK-OV-3.ipl cell line was established from ascites that developed in a nu/nu mouse given an intraperitoneal injection of the SK-OV-3 human ovarian carcinoma cell line (obtained from American Type Culture Collection) as described previously (5-7). Cells were grown in Dulbecco's modified Eagle's medium/nutrient mixture F-12 supplemented with 10% fetal bovine serum. Cells were routinely serum-starved (and therefore deprived of serum HA) before adding HA.
Antibodies and Reagents-Rat anti-CD44 monoclonal antibody (clone 020, isotype IgG 2b ; obtained from CMB-TECH, Inc., San Francisco, CA) recognizes a common determinant of the HA-binding region of CD44 isoforms, including CD44s, CD44E, and CD44 variant species. This rat anti-CD44 antibody was routinely used for HA-related blocking experiments. Both mouse anti-IQGAP1 and rabbit anti-phospho-ER␣ antibodies were purchased from Upstate Cell Signaling Solutions (Lake Placid, NY). A number of immunoreagents, including rabbit anti-Elk-1, mouse anti-phospho-Elk-1, and goat anti-actin antibodies, were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Other immunoreagent such as mouse anti-Cdc42, rabbit anti-ERK, rabbit anti-ERK2, and rabbit anti-phospho-ERK antibodies were purchased from BD Biosciences, Oncogene Research Products (San Diego, CA), and Cell Signaling Technology (Beverly, MA). Mouse anti-ER␣ antibody and recombinant ER␣ were manufactured by Lab Vision Corp. (Freemont, CA) and Calbiochem, respectively. 17␤-[
3 H]Estradiol (specific radioactivity of 52 Ci/mmol) was purchased from Amersham Biosciences. Water-soluble ␤-estradiol was obtained from Sigma. High molecular mass Healon HA polymers (ϳ500,000-Da polymers) were prepared by gel filtration chromatography using a Sephacryl S1000 column. The purity of the high molecular mass HA polymers used in our experiments was further verified by anion exchange high performance liquid chromatography. HA polymers were also digested by PH20 hyaluronidase. Both intact HA and PH20 hyaluronidase-treated HA fragments were used for analyzing their effects on biological activities as described under "Results."
Measurement of Cdc42 Activation-SK-OV-3.ipl cells (ϳ5.0 ϫ 10 6 cells) were resuspended in buffer containing 118 mM KCl, 5 mM NaCl, 0.4 mM CaCl 2 , 1 mM EGTA, 1.2 mM magnesium acetate, 1.2 mM KH 2 PO 4 , 25 mM Tris-HCl (pH 7.4), and 20 mg/ml bovine serum albumin. An aliquot of the cell suspension was added to the electroporation cuvette and incubated at 4°C for 5-10 min, followed by the addition of [
35 S]GTP␥S (12.5 Ci). Subsequently, cells were electroporated at 25 microfarads and 2.0 kV/cm, followed by incubation either with HA (50 g/ml) in the presence or absence of rat anti-CD44 antibody (50 g/ml) or with PH20 hyaluronidase-treated HA fragments (50 g/ml) or without any HA treatment at 37°C for 10 min. Subsequently, [
35 S]GTP␥S-labeled cells were washed with phosphate-buffered saline (PBS; pH 7.4) and solubilized in 1.0% Nonidet P-40 with 1 mM GTP, 25 mM magnesium acetate, and protease inhibitors in PBS (pH 7.4). Nonidet P-40-solubilized cells were then incubated with mouse anti-Cdc42 IgG (5 g/ml) plus goat anti-mouse antibody-conjugated beads. The amount of [ 35 S]GTP␥S bound to Cdc42 associated with anti-Cdc42 antibody-conjugated Immunobeads was measured using a ␥-counter. The values expressed in Table I represent an average of triplicate determinations of five experiments with S.D. Ͻ 5%.
Preparations of IQGAP1 siRNA-The siRNA sequence targeting human IQGAP1 (from the mRNA sequence, GenBank TM /EBI accession number AJ251595) corresponds to the coding region relative to the first nucleotide of the start codon. Target sequences were selected using the software developed by Ambion Inc. As recommended by Ambion Inc., IQGAP1-specific targeted regions were selected beginning 50 -100 nucleotides downstream from the start codon. Sequences with close to 50% G/C content were chosen. Specifically, the IQGAP1 target sequence 5Ј-AAAGTTCTACGGGAAGTAATT-3Ј and scrambled sequence 5Ј-AATAGAGGCAAGGGGTTACG-3Ј were used. The IQGAP1-specific target sequence was then aligned with the human genome data base in a BLAST search to eliminate sequences with significant homology to other genes. Sense and antisense oligonucleotides were provided by the Biomolecular Research Unit of the University of California at San Francisco. For construction of the siRNA, a transcription-based Silencer TM siRNA construction kit (Ambion Inc.) was used. SK-OV-3.ipl cells were then transfected with siRNA using siPORT lipid as transfection reagent (Silencer TM siRNA transfection kit, Ambion Inc.) according to the manufacturer's protocol. Cells were incubated with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA for at least 48 h before biochemical experiments and/or functional assays were conducted as described below.
Immunoblotting and Immunoprecipitation Techniques-SK-OV-3.ipl cells were serum-starved for 24 h, followed by incubation with or without 50 g/ml HA or PH20 hyaluronidase-treated HA fragments for various time intervals (e.g. 0, 1, 3, 5, 7, 10, or 15 min) at 37°C. Subsequently, cells were solubilized in 50 mM HEPES (pH 7.5), 150 mM NaCl, 20 mM MgCl 2 , 0.5% Nonidet P-40, 0.2 mM Na 3 VO 4 , 0.2 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 5 g/ml aprotinin and immunoblotted using various immunoreagents (e.g. rabbit anti-IQGAP1, anti-ERK, anti-ER␣, anti-phospho-ER␣, or anti-actin antibody; 5 g/ml). In some experiments, immunoblot analyses of IQ-GAP1, Cdc42, ERK, Elk-1, ER␣, or CD44 in cells transfected with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA were also carried out.
In some cases, SK-OV-3.ipl cells transfected with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA were incubated with or without 50 g/ml HA for various time intervals (e.g. 0, 1, 3, 5, 7, 10, or 15 min). These cells were extracted with Nonidet P-40 (as described above) and subjected to immunoprecipitation using rat anti-CD44 or rabbit anti-IQGAP1 antibody, followed by goat anti-rabbit IgG. The immunoprecipitated material was solubilized in SDS sample buffer, electrophoresed, and blotted onto nitrocellulose. After blocking nonspecific sites with 3% bovine serum albumin, the nitrocellulose filter was incubated with various antibodies (e.g. rabbit anti-IQGAP1, rat anti-CD44, rabbit anti-Cdc42, anti-ERK, or anti-phospho-ERK antibody; 5 g/ml) for 1 h at room temperature, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:10,000 dilution) at room temperature for 1 h. The blots were then developed using ECL chemiluminescent reagent (Amersham Biosciences) according to the manufacturer's protocols.
IQGAP1 was purified at 4°C from Nonidet P-40-solubilized cell extracts employing three sequential chromatographic steps by fast protein liquid chromatography and media from Amersham Biosciences as described previously (33) . To demonstrate the Rho GTPase-binding properties of IQGAP1, purified IQGAP1 (isolated from SK-OV-3.ipl cells) was incubated with GDP-or GTP-loaded forms of Cdc42-GSTconjugated beads. Proteins associated with Cdc42-GST-conjugated beads were then analyzed by immunoblotting with anti-IQGAP1 antibody as described above.
ERK2-mediated Protein Phosphorylation in Vitro-ERK2 was prepared by anti-ERK2 antibody-conjugated immunoaffinity chromatography. The ERK2 kinase reaction was then carried out in 50 l of kinase buffer containing 25 mM Tris-HCl (pH 7.5), 5 mM ␤-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 , 0.1% CHAPS, 0.1 M calyculin A, 200 M ATP, 100 ng of ERK2 (isolated from SK-OV-3.ipl cells transfected with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA in the presence or absence of 50 g/ml HA), and 1 g of Elk-1 (obtained from anti-Elk-1 antibody-conjugated beads). After incubation for various time intervals (0, 10, 20, 30, 60, and 120 min) at 30°C, the reaction mixtures were boiled in SDS sample buffer and subjected to SDS-PAGE. The protein bands were revealed by immunoblotting with anti-phospho-Elk-1 and anti-Elk-1 antibodies.
In some experiments, the kinase assays was conducted using ERK2 (isolated from anti-ERK2 antibody-conjugated beads using SK-OV-3.ipl cells transfected with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA in the presence or absence of 50 g/ml HA) in 1 ml of kinase buffer supplemented with 200 M [ 32 P]ATP and 18 pM recombinant ER␣ at 30°C for 30 min. Reactions were terminated by the addition of 20% cold trichloroacetic acid, and 2 mg/ml bovine serum albumin was then added as a carrier. Trichloroacetic acid-precipitated proteins were spotted onto Whatman No. 3MM filter papers, followed by extensive washing with 10% trichloroacetic acid. The radioactivity associated with trichloroacetic acid-precipitated materials was analyzed by liquid scintillation counting.
Luciferase Reporter Assays for Elk-1-Elk-1 transcriptional activity was determined using a construct encoding a fusion between the Gal4 DNA-binding domain and the transactivation domain of Elk-1 (Gal4-Elk-1) using the PathDetect® Elk-1 Trans-Reporting System (Stratagene, La Jolla, CA). Specifically, SK-OV-3.ipl cells pretreated with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA were transfected with the fusion transactivator plasmid pFA2-Elk-1 (0.2 g/well in 6-well plates) and the reporter plasmid pFR-luc (1 g/well). As an internal control, these transfectants were also cotransfected with ␤-galactosidase (1 g/well) under the control of the cytomegalovirus promoter. After a 24-h incubation, these cells were washed with PBS and left untreated or treated with HA (50 g/ml) or PH20 hyaluronidasetreated HA fragments (50 g/ml) or pretreated with anti-CD44 antibody, followed by addition of HA (50 g/ml). Subsequently, these cells were washed with PBS, lysed, and assayed for luciferase and ␤-galactosidase activities using kits from Promega (Madison, WI). Data were normalized based on ␤-galactosidase activity.
Detection of ER Activation-To analyze the activation of the ER, SK-OV-3.ipl cells pretreated with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA were incubated in growth medium lacking phenol red (steroid-depleted medium) and containing 10% charcoal-treated fetal bovine serum for 4 days prior to transient transfection. These cells were then cotransfected with the luciferase reporter gene (3 g/well; downstream from two EREs; kindly provide by Dr. P. J. Kushner, University of California at San Francisco) and ␤-galactosidase (2 g/ well) under the control of the cytomegalovirus promoter (as an internal control) for 18 h. Subsequently, cells were washed twice with serumfree steroid-depleted medium and incubated with various reagents (e.g. no HA, HA (50 g/ml), PH20 hyaluronidase-treated HA fragments (50 g/ml), or anti-CD44 antibody (50 g/ml) plus HA (50 g/ml)). These cells were washed with PBS, lysed, and assayed for luciferase and ␤-galactosidase activities using kits from Promega. Data were normalized based on ␤-galactosidase activity.
Analyses of Estrogen Binding in SK-OV-3.ipl Cells-SK-OV-3
.ipl cells grown in steroid-depleted medium and 10% charcoal-treated fetal bovine serum were plated overnight in 6-well plates at 40% confluence, followed by washing twice with serum-free steroid-depleted medium. These cells were then incubated at 37°C for 45 min with 1 ml of serum-free steroid-depleted medium containing 0.091-54 nM 17␤-[ 3 H]estradiol in the presence or absence of a 100-fold excess of nonradioactive 17␤-estradiol to measure nonspecific binding. Subsequently, the medium was removed, and the cells were washed twice with PBS. Cell-bound 17␤-[ 3 H]estradiol was extracted by ethanol treatment, and radioactivity was analyzed by liquid scintillation counting.
F-actin Binding Assays-To study the binding interaction between CD44-associated Cdc42-IQGAP1 and F-actin, CD44-associated Cdc42-IQGAP1-conjugated beads (isolated from SK-OV-3.ipl cells transfected with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA in the presence or absence of HA (50 g/ml) or PH20 hyaluronidase-treated HA fragments (50 g/ml) or pretreated with anti-CD44 antibody, followed by HA addition as described above)) in 50 l of 50 mM Tris-HCl (pH 7.4), 134 mM KCl, and 1 mM MgCl 2 were mixed with an equal volume of 8 M
125
I-labeled F-actin, followed by a 30-min incubation at room temperature. Following binding, the CD44-associated Cdc42-IQ-GAP1-conjugated beads were washed extensively with binding buffer and analyzed by liquid scintillation counting. The amount of F-actin that bound to the CD44-associated Cdc42-IQGAP1-conjugated beads isolated from untreated SK-OV-3.ipl cells (control) or from SK-OV-3.ipl cells treated with scrambled siRNA is designated as 100%. Each assay was set up in triplicate and repeated at least three times. All data were analyzed statistically using Student's t test, and statistical significance was set at p Ͻ 0.01.
Tumor Cell Migration Assays-Twenty-four Transwell units were used for monitoring in vitro cell migration as described previously (16, 17) . Specifically, 5-m porosity polycarbonate filters (Costar Corp., Cambridge, MA) were used for the cell migration assay. SK-OV-3.ipl cells (transfected with or without 50 pmol of IQGAP1 siRNA or scrambled siRNA in the presence or absence of rat anti-CD44 antibody (50 g/ml)) were placed in the upper chamber of the Transwell unit. Medium lacking or containing HA (50 g/ml) or PH20 hyaluronidasetreated HA fragments (50 g/ml) was placed in the lower chamber of the Transwell unit. After an 18-h incubation at 37°C in a humidified 95% air and 5% CO 2 atmosphere, cells on the upper side of the filter were removed by wiping with a cotton swap. Cell migration processes were determined by measuring the cells that migrated to the lower side of the polycarbonate filters by standard cell number counting methods as described previously (74, 75) . The CD44-specific cell migration was determined by subtracting nonspecific cell migration (i.e. cells that migrated to the lower chamber in the presence of anti-CD44 antibody treatment). Each assay was performed in triplicate and repeated at least five times. The number of ovarian tumor cells that migrated in untreated SK-OV-3.ipl cells (control) or in SK-OV-3.ipl cells treated with scrambled siRNA is designated as 100%. All data were analyzed statistically by Student's t test, and statistical significance was set at p Ͻ 0.01.
RESULTS

HA-stimulated Cdc42 Signaling and CD44-IQGAP1 Association in Ovarian Tumor
Cells-The binding of HA to CD44 is known to induce important changes in certain Rho GTPases such as Cdc42 (19 -21) . Using an in vitro [ 35 S]GTP␥S binding assay, we determined that Cdc42 isolated from SK-OV-3.ipl human ovarian tumor cells displays specific guanine nucleotide-binding activity (Table I) . In particular, we demonstrated that the addition of HA to CD44-containing SK-OV-3.ipl cells caused almost a 3-fold increase in the binding of [ 35 S]GTP␥S to Cdc42 compared with the amount of binding present in untreated SK-OV-3.ipl cells (Table I ) or in SK-OV-3.ipl cells pretreated with anti-CD44 antibody, followed by HA treatment (Table I) . To rule out the possibility that Cdc42 activation was mediated by potential contaminants in our HA preparation, SK-OV-3.ipl cells were also incubated with PH20 hyaluronidase-treated HA fragments. Our results show that no significant Cdc42 activation was detected in cells treated with PH20 hyaluronidase-digested HA fragments compared with intact HA (Table I ). These findings indicate that intact HA (not contaminants in the intact HA preparation or in hyaluronidasetreated HA fragments) and CD44 are directly involved in Cdc42 signaling in human ovarian tumor cells.
A large number of Cdc42-associated proteins are known to play important roles in signal transduction and various cellular functions (18) . One of the known binding partners for the GTP-bound (activated) form of Cdc42 is IQGAP1 (28 -34) . Using a specific anti-IQGAP1 antibody-mediated immunoblot technique, we found that significant amounts of IQGAP1 (molecular mass of ϳ190 kDa) were expressed in SK-OV-3.ipl cells (Fig. 1A, lane 2) . We believe that the IQGAP1 detected in SK-OV-3.ipl cells is specific since no protein was detected in these cells using preimmune rabbit IgG (Fig. 1A, lane 1) . Several lines of evidence have indicated that IQGAP1 binds to Rho GTPases such as Cdc42 (28 -34) . In this study, we incubated purified IQGAP1 (isolated from SK-OV-3.ipl cells) with GDPor GTP-loaded forms of Cdc42-GST-conjugated beads. Proteins associated with Cdc42-GST-conjugated beads were then analyzed by immunoblotting with anti-IQGAP1 antibody (Fig. 1B) . Our results show that a large amount of IQGAP1 associated with GTP-bound Cdc42-GST-conjugated beads (Fig. 1B, lane  2) , whereas a lower level of IQGAP1 bound to GDP-bound Cdc42 (lane 1). These results suggest that IQGAP1 interacts directly with Cdc42 in a GTP-dependent manner.
In addition, we addressed the question of whether there is a physical linkage between CD44 and IQGAP1 (and/or Cdc42) in SK-OV-3.ipl ovarian tumor cells. To this end, we first carried out immunoprecipitation with anti-CD44 antibody, followed by anti-IQGAP1 antibody immunoblotting (Fig. 1C, panel a) or anti-CD44 antibody immunoblotting (panel c) using untreated cells or cells treated with HA. Our results indicate that HA treatment caused the recruitment of a significant amount of IQGAP1 (Fig. 1C, panel a, lane 2) into the CD44 complex (panel c, lane 2). In contrast, a low level of IQGAP1 (Fig. 1C, panel a,  lane 1) was present in the anti-CD44 antibody-immunoprecipitated materials (reblotted with anti-CD44 antibody) in untreated cells (Fig. 1C, panel c, lane 1) or in cells pretreated with anti-CD44 antibody, followed by HA treatment (panels a and c, lanes 3). We also observed that the recruitment of IQGAP1 to CD44 was greatly reduced in cells incubated with PH20 hyaluronidase-treated HA fragments compared with intact HA . In addition, we noticed that the Cdc42 association (Fig. 1C, panel b, lane 4) with IQGAP1 (panel a, lane 4) and CD44 (panel c, lane 4) was relatively low in cells incubated with PH20 hyaluronidasetreated HA fragments compared with intact HA (panels a and c, lanes 4). These observations suggest that intact HA (not contaminants in the intact HA preparation or in hyaluronidase-treated HA fragments) promotes Cdc42 binding to the CD44-IQGAP1 complex in ovarian tumor cells. Furthermore, the results of an in vitro F-actin binding assay indicate that the HA-CD44-induced Cdc42-IQGAP1 complex was capable of forming a stable ternary structure containing Cdc42, IQGAP1, and F-actin (Table II) . Very little F-actin binding to these Cdc42-IQGAP1 complexes (isolated either from untreated cells or from cells pretreated with anti-CD44 antibody, followed by HA addition) was detected using these binding assays (Table  II) . We observed that F-actin binding to the Cdc42-IQGAP1 complexes (isolated from cells incubated with PH20 hyaluronidase-treated HA fragments) was also very low (Table II) . These observations suggest that the HA-CD44-induced Cdc42-IQ-GAP1 complex is involved in the F-actin binding required for microfilament organization.
HA-CD44-induced IQGAP1 Signaling in the Regulation of ERK Activation and ERK-mediated Elk-1 Phosphorylation and
Transcriptional Activation in SK-OV-3.ipl Cells-HA signaling also stimulates ERK activity (50, 51) . ERK is known to be activated by phosphorylation of threonine residues (43, 44) . Using anti-ERK antibody-mediated immunoblot analysis, we found that both ERK1 and ERK2 were expressed in SK-OV-3.ipl cells incubated under various conditions (e.g. untreated ( Fig. 2A, panel b, lane 1) , treated with HA (lane 2), or pretreated with anti-CD44 antibody, followed by HA treatment (lane 3)). We also observed that ERK2 (and to a lesser extent, ERK1) phosphorylation was significantly up-regulated by HA treatment as detected by anti-phospho-ERK antibody-mediated immunoblotting (Fig. 2A, panel a, lane 2) . The level of ERK2 phosphorylation was relatively low in untreated cells (Fig. 2A, panel a, lane 1) or in cells pretreated with anti-CD44 antibody, followed by HA treatment (lane 3). Our observations 
of F-actin binding to the CD44-associated Cdc42-IQGAP1 complex isolated from SK-OV-3.ipl cells
The procedures for measuring 125 I-labeled F-actin binding to the CD44-Cdc42-IQGAP1 complex using SK-OV-3.ipl cells (treated with HA (50 g/ml) or PH20 hyaluronidase-treated HA fragments (50 g/ml); pretreated with rat anti-CD44 IgG, followed by HA addition (50 g/ml); without HA treatment; without siRNA transfection; or transfected with 50 pmol of IQGAP1 siRNA scrambled sequences or 50 pmol of IQGAP1 siRNA target sequence in the presence or absence of 50 g/ml HA) were described under "Materials and Methods." Each assay was set up in triplicate and repeated at least three times. The amount of F-actin binding to the CD44-associated Cdc42-IQGAP1 complex isolated from untreated SK-OV-3.ipl cells (Part A) or from SK-OV-3.ipl cells treated with scrambled siRNA (Part B) is designated as 100%. All data were analyzed statistically using Student's t test, and statistical significance was set at p Ͻ 0.01. strongly support the conclusion that HA-mediated ERK phosphorylation is CD44-dependent. A recent study by Roy et al. (37) showed that IQGAP1 and ERK2 form a complex both in vitro and in vivo. In this study, we observed that the association between IQGAP1 (Fig. 2B, panel c, lane 2) and ERK2 (panel b, lane 2) or phosphorylated ERK2 (panel a, lane 2) was greatly enhanced in SK-OV-3.ipl cells treated with HA compared with untreated cells (panels a-c, lanes 1) or in cells pretreated with anti-CD44 antibody, followed by HA treatment (panels a-c, lanes 3) . Treatment of cells with PH20 hyaluronidase-treated HA fragments failed to stimulate IQGAP1 accumulation (Fig. 2B, panel c, lane 4) into a ERK2 complex (panel b, lane 4) and phosphorylation of ERK2 (Fig. 2, A, panels a and  b, lanes 4; and B, panel a, lane 4) . Therefore, we believe that IQGAP1 functions as a scaffolding protein that effectively recruits ERK (in particular, phosphorylated ERK2) into the multimolecular complex containing CD44 and Cdc42 during cellular signaling by intact HA in ovarian tumor cells.
Previous studies have indicated that ERK phosphorylation is a critical determinant of the ability of ERK to phosphorylate cellular substrates such as Elk-1 and to stimulate transcriptional activity (45, 46) . In this study, we measured the kinase activity associated with the ERK molecule (in particular, ERK2) isolated from SK-OV-3.ipl cells (Fig. 3) . Specifically, the kinase activity was determined by the ability of ERK2 to phosphorylate purified Elk-1. Fig. 3A (lane 2) shows that IQGAP1-linked ERK2 isolated from HA-treated cells was clearly capable of phosphorylating Elk-1 in the in vitro kinase assay. The amount of Elk-1 phosphorylation was very low using IQGAP1-bound ERK2 prepared from untreated cells (Fig. 3A, lane 1) . These results confirm that IQGAP1-associated ERK2 (stimulated by HA-CD44 signaling) is functionally active. Additional analyses indicated that the level of Elk-1 phosphorylation in vivo as detected using anti-phospho-Elk antibody (Fig. 3B, panel a) was significantly enhanced in SK-OV-3.ipl cells treated with HA (panels a and b, lanes 2) . In contrast, Elk-1 phosphorylation was relatively low in SK-OV-3.ipl cells without any HA treatment (Fig. 3B, panels a and b, lanes 1) or in SK-OV-3.ipl cells pretreated with anti-CD44 antibody, followed by HA treatment (panels a and b, lanes 3) . Cells incubated with PH20 hyaluronidase-treated HA fragments showed very little induction of Elk-1 phosphorylation (Fig. 3B, panels a  and b, lanes 4) . These observations strongly suggest that Elk-1 phosphorylation (possibly via ERK activation) stimulated by intact HA is CD44-dependent.
In addition, we measured Elk-1-driven gene transcription using a construct encoding a fusion between the Gal4 DNAbinding domain and the transactivation domain of Elk-1 (Gal4-Elk-1). Specifically, SK-OV-3.ipl cells were transfected with Gal4-Elk-1 fusion and firefly luciferase reporter constructs. Fig. 3C shows that Elk-1 transactivation activity was significantly stimulated in cells treated with HA (bar b) compared with Elk-1 transcriptional activity in untreated cells (bar a) or in cells pretreated with anti-CD44 antibody, followed by HA treatment (bar c). In the presence of PH20 hyaluronidasetreated HA fragments, the transcriptional activation of Elk-1 detected in SK-OV-3.ipl cells was very low (Fig. 3C, bar d) . These observations strongly indicate that CD44-associated IQ-GAP1-ERK signaling is involved in HA-dependent Elk-1 phosphorylation and Elk-1-regulated transactivation in ovarian tumor cells. (47, 52) . Fig. 4a shows a representative example of a saturation binding curve involving 17␤-[ 3 
HA-CD44-induced IQGAP1 Signaling in the Regulation of ERK-mediated ER␣ Phosphorylation and Transcriptional Activation in SK-OV-3.ipl Cells-The action of the ER (in particular, ER␣) is known to be regulated by the binding of its ligand (estrogen) or by input from signal transduction cascades
H]estradiol and ERs in SK-OV-3.ipl cells (in vivo)
. Saturation binding occurred at a ligand concentration of ϳ55 nM. Moreover, the Scatchard plot analysis presented in Fig. 4b indicates that 17␤-[ 3 H]estradiol bound to the ER at a single site with high affinity (an apparent dissociation constant (K d ) of Ϸ7.0 nM). Using a specific anti-ER␣ antibody-mediated immunoblot technique, we determined that ER␣ (molecular mass of ϳ67 kDa) was the major ER expressed in SK-OV-3.ipl cells (Fig. 4c) . EGF stimulation of MAPKs such as ERK1 and ERK2 has been shown to phosphorylate ER␣ at Ser 118 in the N-terminal domain and to enhance transcriptional activity (47, 48, 54) . The question of whether HA-CD44-induced IQGAP1 signaling and ERK2 activation are capable of causing ER␣ phosphorylation and transcriptional activation in ovarian tumor cells has not been addressed previously.
In searching for a possible linkage between HA-CD44-mediated IQGAP1 signaling and ERK and ER␣ function, we demonstrated that IQGAP1-linked ERK2 isolated from SK-OV-3.ipl cells treated with HA was capable of phosphorylating ER␣ in vitro (Fig. 5A, bar b) . A much lower level of ER␣ phosphorylation was detected in untreated cells (Fig. 5A, bar a) . These findings indicate that ER␣ serves as a cellular substrate for HA-CD44-activated and IQGAP1-linked ERK2 in vitro. 5B (panels a and b, lanes 2) shows that the level of ER␣ phosphorylation in vivo (as detected by anti-phospho-ER␣ antibody) was also greatly enhanced in SK-OV-3.ipl cells treated with HA. The amount of HA-mediated ER␣ phosphorylation was similar to that of estrogen-induced ER␣ phosphorylation (Fig. 5B, panels a and b, lanes 5) . In contrast, ER␣ phosphorylation was very low in untreated SK-OV-3.ipl cells (Fig. 5B,  panels a and b, lanes 1 ) or in SK-OV-3.ipl cells pretreated with anti-CD44 antibody, followed by HA treatment (panels a and b, lanes 3). Treatment of cells with PH20 hyaluronidase-digested HA fragments did not reveal any significant stimulation of ER␣ phosphorylation (Fig. 5B, panels a and b, lanes 4) . Therefore, we believe that ER␣ phosphorylation also occurs in vivo (via IQGAP1-ERK activation events) during HA-CD44 interaction similar to estrogen binding in ovarian tumor cells such as SK-OV-3.ipl cells.
Next, we examined the potential impact of ER␣ phosphorylation on the regulation of ERE gene activation. Fig. 5C shows that the level of ERE gene activity was low in untreated cells (bar a) or in cells pretreated with anti-CD44 antibody, followed by HA treatment (bar c). ERE gene activity was greatly enhanced in SK-OV-3.ipl cells treated with intact HA (Fig. 5C,  bar b) . In contrast, cells treated with PH20 hyaluronidasedigested HA fragments did not show any increase in ERE gene activation (Fig. 5C, bar d) . The level of HA-stimulated ERE transcriptional activation (Fig. 5C, bar b) appeared to be comparable with that detected following estradiol treatment (bar e). These findings clearly indicate that intact HA induces ERmediated nuclear activation and/or transcriptional up-regulation in a CD44-dependent manner in SK-OV-3.ipl cells.
Effects of IQGAP1 siRNA on HA-CD44-mediated Cdc42-Actin Binding, ERK Activation, and Ovarian Tumor Cell Migration-Transfection of mammalian cells with synthetic siRNAs (21-23 nucleotides in length) specifically suppresses expression of endogenous and heterologous genes by RNA interference (58 -60) . To confirm that IQGAP1 is a signaling regulator responsible for specific downstream effector functions (e.g. recruiting CD44, Cdc42, and ERK2 into a multimolecular complex; mediating Cdc42-actin binding; activating ERK signaling; and stimulating Elk-1/ER␣-mediated transcriptional activities and tumor cell migration) during HA-CD44 interaction, we transfected SK-OV-3.ipl cells with a specific siRNA sequence targeting human IQGAP1. Fig. 6A (panel a, lane 2) clearly demonstrates that the IQGAP1 siRNA target sequence used successfully suppressed the expression of IQGAP1 in SK-OV-3.ipl cells. In control samples, no IQGAP1 down-regulation was observed in SK-OV-3.ipl cells treated with transfection reagents containing scrambled sequences (Fig. 6A, panel a, lane  1) . Because other cellular proteins such as Cdc42 (Fig. 6A,  panel Additional analyses indicated that "knocking down" IQGAP1 by transfecting SK-OV-3.ipl cells with IQGAP1 siRNA significantly inhibited IQGAP1 interaction with Cdc42 and CD44 (Fig. 6B, panels a and b, lanes 3 and 4) and/or ERK2 and phospho-ERK2 (Fig. 6C, panels a and b, lanes 3 and 4) . Specifically, the formation of the CD44-Cdc42-IQGAP1 complexes (Fig. 6B, panels a and b, lanes 2) or IQGAP1-ERK2 and IQ-GAP1-phospho-ERK2 complexes (Fig. 6C, panels a and b, lanes 2) was greatly enhanced in SK-OV-3.ipl cells treated with scrambled siRNA plus HA compared with those cells treated with scrambled siRNA but no HA (Fig. 6B, panels a and b,  lanes 1; and Fig. 6C, panels a and b, lanes 1) . However, the recruitment of Cdc42, CD44, and ERK into the IQGAP1 complex was completely abolished in cells treated with IQGAP1 siRNA in the presence of HA (Fig. 6B, panels a and b, lanes 4; and Fig. 6C, panels a and b, lanes 4) or absence of HA (Fig. 6B,  panels a and b, lanes 3; and Fig. 6C, panels a and b, lanes 3) . Down-regulation of IQGAP1 by treating cells with IQGAP1 siRNA also significantly inhibited HA-activated Cdc42-IQ-GAP1-actin binding (Table II) and blocked ERK signaling (e.g. (Fig. 7A, lane 4) and in vivo (Fig. 7B, lane 4) , ER␣ phosphorylation in vitro (Fig.  7D, bar d) and in vivo (Fig. 7E, lane 4) , and Elk-1/ERE transcriptional activation) in cells incubated with HA (Fig. 7C, bar  d; and Fig. 7F , bar d) compared with those signaling events detected in cells treated with scrambled siRNA (Fig. 7A, lanes  1 and 2; Fig. 7B, panels a and b, lanes 1 and 2; Fig. 7C, bars a  and b; Fig. 7D, bars a and b; Fig. 7E, panels a and b, lanes 1 and  2; and Fig. 7F, bars a and b) .
ERK-mediated
Furthermore, using in vitro migration assays, we observed that SK-OV-3.ipl cells actively migrated during HA treatment (Table III) . However, the level of tumor cell migration appeared to be very low in SK-OV-3.ipl cells treated with PH20 hyaluronidase-digested HA fragments (Table III) . Pretreatment of SK-OV-3.ipl cells with certain reagents such as anti-CD44 antibody and cytochalasin D (an inhibitor known to impair filamentous actin function) also caused a significant inhibition of HA-mediated tumor cell migration (Table III) . Importantly, transfection of SK-OV-3.ipl cells with IQGAP1 siRNA (but not scrambled siRNA) also effectively blocked CD44-cytoskeletondependent and HA-specific SK-OV-3.ipl tumor cell migration (Table III) . Together, these findings support the conclusion that IQGAP1 acts as an important signaling regulator of HAinduced Cdc42-actin interaction, ERK signaling, Elk-1/ER␣-mediated transcriptional activation, and tumor cell migration.
DISCUSSION
CD44 isoforms are a family of transmembrane glycoproteins composed of a variable extracellular domain, a single transmembrane-spanning domain, and a cytoplasmic domain (61) . Nucleotide sequence analyses revealed that many CD44 isoforms (derived from alternative splicing mechanisms) are variants (referred to as CD44v) of the standard form, CD44s (61) . The presence of high levels of CD44s (often together with CD44v) is emerging as an important metastatic tumor marker in a number of carcinomas and is also associated with an unfavorable prognosis for a variety of cancers, including human ovarian cancers (8, 9, 13, 14) .
HA is the major glycosaminoglycan found in the extracellular matrix of mammalian tissues. It is well known that extracellular matrix components such as HA are also present in large amounts in the mesothelial lining of the peritoneum (8, 9, 13, 14) . Furthermore, hyaluronan often accumulates at sites of ovarian tumor cell attachment (8, 9, 13, 14) . CD44 is considered to be one of the major HA receptors (4). Specific HA-binding motifs have been identified and localized in the extracellular domain of CD44 (10 -12) . The binding of HA to CD44 is known to be involved in the onset of a variety of biological activities, including Ca 2ϩ mobilization; receptor redistribution; cell adhesion, proliferation, migration, and aggregation; gene expression, angiogenesis; and tumor metastasis (5-7, 15-19, 24, 25, 62-68) .
Previous studies have indicated that the intracellular domain of CD44 binds to certain cytoskeletal proteins such as ankyrin and the ERM proteins (exrin, radixin, and moesin) (19 -21) . Post-translational modification of the CD44 cytoplasmic domain by acylation (69), serine/threonine kinase-mediated phosphorylation (19, 70, 71) , or GTP binding (72) enhances the binding between CD44 and cytoskeletal proteins. Thus, the transmembrane interaction between CD44 isoforms and ankyrin/ERM provides a direct link between the extracellular matrix and the cytoskeleton.
Accumulating evidence indicates that certain Rho GTPaserelated signaling molecules are structurally and functionally coupled with the cytoplasmic domain of CD44 (10, GTP-bound form, they often interact with specific downstream target(s) and initiate a series of biological activities (18) . Previous studies have indicated that HA-CD44 interaction induces activation of Rho GTPases (such as RhoA and Rac1), resulting in cytoskeletal reorganization, actomyosin-based cytoskeletal function, and tumor progression (7, 17, 19) . In particular, selective interaction of the CD44 cytoplasmic domain with RhoAactivated Rho kinase (19) and Rho/Rac1-specific guanine nucleotide exchange factors (p115RhoGEF (17), Tiam1 (62) , and Vav2 (7)) has been shown to play an important role in promoting invasive and metastatic tumor phenotypes.
As part of our continuing effort to identify CD44 isoformlinked Rho GTPase signaling components that correlate with certain metastatic behaviors, a new candidate molecule named IQGAP1 (a Cdc42/Rac1-binding protein) has been identified. The IQGAP family of proteins has been identified in yeast, amoebas, and mammals (26, 27) . There are at least three different isoforms of IQGAP (IQGAP1, IQGAP2, and IQGAP3) detected in mammals (27) . At the present time, IQGAP1 is the best characterized isoform, whereas very little information is currently known regarding either IQGAP2 or IQGAP3. Therefore, we have focused our investigation on IQGAP1, which has been shown to contain several protein-protein interaction domains (e.g. a calponin homology domain, four IQ motifs, and a Ras GTPase-activating protein-related domain) and to be associated with a number of diverse target molecules (26, 27) . Using an IQGAP1-specific antibody, we have confirmed the presence of IQGAP1 in SK-OV-3.ipl human ovarian tumor cells (Fig. 1) . IQGAP1 and the cell-surface molecules CD44 and Cdc42 were closely associated in a complex in human ovarian tumor cells following HA stimulation (Fig. 1) . Several lines of evidence indicate that IQGAP1 has cross-linking activity for F-actin that is augmented by GTP-bound active Cdc42 (30, 35, 36) . We have also demonstrated that the HA-induced CD44-Cdc42-IQGAP1 complex is capable of binding to F-actin (Table II) . These findings are consistent with previous reports showing that Cdc42-IQGAP1 plays an important role in controlling the dynamics of actin assembly (30, 35, 36) . The physiological significance of the in vitro F-actin-binding properties of the purified CD44-Cdc42-IQGAP1 complex was further bolstered by the observation that the down-regulation of IQGAP1 by treating cells with IQGAP1 siRNA resulted in the disappearance of the CD44-Cdc42-IQ-GAP1 complex (Fig. 6) , the reduction of F-actin binding to the CD44-Cdc42-IQGAP1 signaling complex (Table II) , and the inhibition of HA-CD44-mediated ovarian tumor cell migration (Table III) . These results are consistent with our findings indicating that disruption of the F-actin structure by treating cells with cytochalasin D caused a significant reduction in HA-CD44-mediated ovarian tumor cell migration (Table III) . These observations further support the likelihood that CD44-Cdc42-IQGAP1 complex formation is one of the critical steps in regulating F-actin binding required for HA-CD44-mediated cytoskeletal function and ovarian tumor cell migration.
Previously, we reported that HA binding to the CD44-p185 HER2 complex promotes Ras signaling, which may be one of the important signaling events in human ovarian carcinoma development (5) . Ras stimulation is known to promote a downstream kinase cascade, including Raf-1/MEK/ERK pathways (43, 44) . The MAPKs ERK1 and ERK2 are ubiquitous protein kinases that transmit and integrate cell-surface signals by phosphorylating target proteins throughout the cell. In particular, ERK signaling is closely associated with ovarian cancer progression (55) (56) (57) . Therefore, an understanding of how ERK activation is regulated will provide important insight into the disease mechanisms related to cancer progression. ERK kinase signaling is a multistep process involving self-phosphorylation, which is required for the enzyme (kinase) to be able to phosphorylate other key substrates and to influence cell behaviors. During Ras signaling, the MAPKs ERK1 and ERK2 are phosphorylated and activated by the MAPK kinases MEK1 and MEK2, which are in turn phosphorylated and activated by ERK/MAPK kinase kinases, which are members of the Raf-1 family (43, 44) .
Although ERK phosphorylation and activation of the Ras/ Raf-1/MEK/ERK signaling cascade are important, it is also possible that other signaling pathway(s) may be involved in the activation of ERK. In fact, a recent study indicated that IQ-GAP1 plays an important role in ERK binding, phosphorylation, and activation during EGF/insulin-like growth factor signaling in breast tumor cells (e.g. MCF cell lines) (37) . In this study, we have demonstrated that IQGAP1 is capable of binding to ERK2 (and to a lesser extent, ERK1) and inducing marked phosphorylation of ERK2 in ovarian tumor cells (Fig.  2) . Moreover, both ERK2 phosphorylation and kinase activity (associated with IQGAP1) (Fig. 2) could be stimulated by HA and blocked by cells pretreated with anti-CD44 antibody during HA stimulation ( Fig. 2 and Table I ). Thus, it appears that IQGAP1-associated ERK2 phosphorylation and activity are closely coupled with HA-mediated CD44 activation in ovarian tumor cells. Additional analyses indicated that reduction of IQGAP1 expression and IQGAP1-ERK2 complex formation resulted in inhibition of ERK2 phosphorylation (Fig. 6 ) and activity (Fig. 7) . These findings strongly support the conclusion that IQGAP1 is directly involved in ERK2 binding and ERK phosphorylation and activity during HA-mediated CD44 signaling in ovarian tumor cells.
The ternary complex factors such as Elk-1 belong to a family of extracellular signal-regulated transcription factors (45, 46) . ERK activation often induces phosphorylation of Elk-1 at multiple serine and threonine phosphorylation motifs (45, 46) . Functional studies have shown that Elk-1 phosphorylation potentiates transcriptional activation and DNA binding (45, 46) . In this study, we found that ERK-mediated phosphorylation of ELK up-regulated transcriptional activity in an HA-specific and CD44-dependent manner (Fig. 3) . Most importantly, treatment of cells with an IQGAP1-specific siRNA (which effectively down-regulates the expression of IQGAP1 in SK-OV-3.ipl cells) (Fig. 6 ) not only blocked HA-CD44-stimulated IQGAP1 association with ERK2 and/or ERK2 phosphorylation (Fig. 6 ), but also impaired ERK-mediated Elk-1 phosphorylation and Elk-1-activated transcriptional activity (Fig. 7) . These findings suggest that IQGAP1-activated ERK (in particular, ERK2) acts as one of the important upstream activators for Elk-1 function required for HA-CD44-mediated transcriptional up-regulation.
Approximately 40 -60% of human ovarian cancers express nuclear hormone receptors such as ER␣ (and to a lesser extent, ER␤) (74, 75) . Recent results from three large prospective studies indicate that the risk of ovarian cancer incidence and mortality is closely associated with the activation of nuclear hormone receptors (in particular, ER␣) (76) . The classical model of 17␤-estradiol action involves ligand-mediated activation of ER␣, which interacts directly with the ERE in the promoters of target genes and recruits specific coactivators to activate transcription (77, 78) . However, signal transduction by growth factors such as EGF and insulin-like growth factor-1 is sometimes sufficient to activate ER␣ in a ligand (estrogen)-independent manner (47, 48) . For example, EGF binding to the EGF receptor stimulates the Ras/Raf-1/MEK signaling cascade, leading to the activation of the MAPKs ERK1 and ERK2, which phosphorylate the ER and allow phosphorylated ER dimers to interact with specific DNA sequences (ERE) within the promoters of responsive genes (47) . In this study, we have determined that SK-OV-3.ipl cells express ER␣ (Fig. 4) , which serves as a cellular substrate for IQGAP1-linked ERK2 in SK-OV-3.ipl cells (Fig. 5 ). In addition, we have demonstrated that ER␣ phosphorylation by IQGAP1-linked ERK2 (isolated from SK-OV-3.ipl cells in the presence of HA treatment) significantly up-regulates ERE transcription (Fig. 5) . In contrast, the reduction of ER␣ phosphorylation by down-regulating IQGAP1 expression and IQGAP1-ERK2 complex formation (using SK-OV-3.ipl cells transfected with IQGAP1 siRNA (but not scrambled sequences) with or without HA treatment) readily abolished ERE transactivation (Fig. 7) . Thus, it is likely that HA-CD44-mediated IQGAP1-ERK2 signaling plays a role in (i) regulating ER␣ phosphorylation and the subsequent ERE transcriptional regulation (in an estrogen-independent manner) and (ii) coordinating cross-talk between the membrane receptor (CD44) and nuclear hormone receptor (ER␣) signaling pathways during ovarian cancer progression.
Both ERK signaling and ER␣ activation ultimately influence cell cycle elements such as cyclin D 1 (46, 47, 52) . Cyclin D 1 is expressed in the G 1 phase of the cell cycle, and complexes of cyclin D 1 and cyclin-dependent kinase are important for the phosphorylation of several key components involved in cell proliferation (78) . Overexpression of cyclin D 1 is associated with poor survival in epithelial ovarian cancers (79, 80) . Our preliminary data indicate that IQGAP1-linked ERK2 activation, Elk-1/ER␣ phosphorylation, and Elk-1/ERE transactivation are also accompanied by a robust induction of cyclin D 1 expression and ovarian tumor cell growth in ovarian tumor cells treated with HA (data not shown). Detailed characterization of the molecular interactions between Elk-1/ER␣-mediated transcriptional activation/coactivators and cyclin D 1 overexpression (contributing to cell cycle progression and/or tumor cell growth) during HA-CD44 and IQGAP1 signaling is currently under way.
Previously, modified HA has been used to promote wound healing and tissue repairs (81) . HA conjugated to anticancer drugs can effectively target HA-overexpressing ovarian tumor cells (53, 73) . We believe that our observations support the notion that CD44-associated IQGAP1 signaling events may also be used as potential drug targets for HA-CD44-related anti-ovarian cancer therapy. As summarized in Fig. 8 , we would like to propose that HA-activated CD44 is tightly coupled with IQGAP1 in a complex that interacts with both Cdc42 (Step 1a) and ERK2 (Step 1b). The CD44-Cdc42-IQGAP1 complex is capable of binding to F-actin required for cytoskeletal function ( Step 2a) and ovarian tumor cell migration (Step 3a) . At the same time, the association of CD44-IQGAP1 with ERK2 (Step 1b) promotes ERK2 phosphorylation and activity (Step 2b), which, in turn, phosphorylates Elk-1 and ER␣ (Step 3b). Most importantly, phosphorylation of Elk-1/ER␣ by IQGAP1-linked ERK2 enhances transcriptional activation (Step 3b). We believe that these oncogenic signaling events and tumor cellspecific behaviors play a pivotal role in promoting ovarian tumor progression.
